RecruitingNot ApplicableNCT06818916

Hetrombopag in Promoting Platelet Engraftment After Auto-HSCT in Children With Neuroblastoma

Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment After Autologous Hematopoietic Stem Cell Transplantation in Children With Neuroblastoma

Sponsor

Beijing Children's Hospital

Enrollment

30 participants

Start Date

Jun 30, 2024

Study Type

INTERVENTIONAL

Conditions

Neuroblastoma Delayed Platelet Engraftment Autologous Hematopoietic Stem Cell Transplantation

Summary

The goal of this clinical trial is to learn if hetrombopag promotes platelet engraftment in neuroblastoma children undergoing autologous hematopoietic stem cell transplantation. The main question it aims to answer is: · Does drug hetrombopag promote platelet engraftment? Participants will take hetrombopag every day for 6 weeks or until platelet \> 100\*10\^9/L.

Eligibility

Max Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a drug called hetrombopag can help children with neuroblastoma recover their platelet counts (blood clotting cells) faster after an autologous stem cell transplant — a procedure that uses the child's own stem cells to rebuild their blood system after high-dose chemotherapy. **You may be eligible if...** - You are under 18 years old - You have been diagnosed with neuroblastoma - You are receiving your first-ever autologous stem cell transplant - You or your legal guardian are willing to sign consent **You may NOT be eligible if...** - Your liver enzymes or bilirubin levels are significantly elevated - You have had heart failure, blood clots, a heart attack, or stroke within the past year - You currently have a blood-clotting disease - Your doctor determines other health conditions make participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHetrombopag

Patients enrolled were administered Hetrombopag starting from +4d after transplantation on routine medication of recombinant human thrombopoietin injection (rhTPO). The starting dose of Hetrombopag is 2.5mg or 5mg, oral, once daily (starting at 5mg/d for body weight\>20kg; starting from 2.5mg/d for body weight ≤ 20kg). Adjust the dosage based on platelet count every two weeks, with a maximum dose of 7.5mg per day. Stop the medication after 6 weeks of continuous use or when PLT reaches 100 × 10\^9/L.

Locations(1)

Department of Stem Cell Transplantation, Beijing Children's Hospital, Capital Medical University

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06818916

Related Trials

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296177 locations

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

NCT069958721 location